Serum Alliance will give revenue stream from H2FY23: Biocon Biologics exec

In a Q&A, Shreehas Tambe talks about the road ahead for the firm's biosimilars business and how its alliance with Serum is projected to pan out

Biocon’s revenue in the quarter ended September rose 10 per cent to Rs 1,945 crore over the corresponding period in the previous financial year, primarily driven by its research services and biosimilars business segments, which reported a growth of 17 per cent and 10 per cent, respectively. The pharma major said that its subsidiary, Biocon Biologics, made strategic moves in the quarter which will drive future growth of the biosimilars segment and deliver long term value for shareholders. In an interview, Biocon Biologics deputy CEO Shreehas Tambe told Deepsekhar Choudhury about the road ahead for its biosimilars business and how